These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 10430108)

  • 21. Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test.
    Michael M; Cullinane C; Hatzimihalis A; O'Kane C; Milner A; Booth R; Schlicht S; Clarke SJ; Francis P
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):125-35. PubMed ID: 21626050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity.
    Kurnik D; Wood AJ; Wilkinson GR
    Clin Pharmacol Ther; 2006 Sep; 80(3):228-34. PubMed ID: 16952489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
    Capon DA; Bochner F; Kerry N; Mikus G; Danz C; Somogyi AA
    Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomes.
    Wang Y; Unadkat JD
    Biopharm Drug Dispos; 1999 Oct; 20(7):341-6. PubMed ID: 10760842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity.
    Ducharme J; Abdullah S; Wainer IW
    J Chromatogr B Biomed Appl; 1996 Mar; 678(1):113-28. PubMed ID: 8861661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of mibefradil on CYP3A4 in vivo.
    Veronese ML; Gillen LP; Dorval EP; Hauck WW; Waldman SA; Greenberg HE
    J Clin Pharmacol; 2003 Oct; 43(10):1091-100. PubMed ID: 14517191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil.
    Choi DH; Shin WG; Choi JS
    Eur J Clin Pharmacol; 2008 May; 64(5):445-9. PubMed ID: 18193210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of CYP3A inhibition on vesnarinone metabolism in humans.
    Wandel C; Lang CC; Cowart DC; Girard AF; Bramer S; Flockhart DA; Wood AJ
    Clin Pharmacol Ther; 1998 May; 63(5):506-11. PubMed ID: 9630823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.
    Lown KS; Mayo RR; Leichtman AB; Hsiao HL; Turgeon DK; Schmiedlin-Ren P; Brown MB; Guo W; Rossi SJ; Benet LZ; Watkins PB
    Clin Pharmacol Ther; 1997 Sep; 62(3):248-60. PubMed ID: 9333100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human.
    Dadashzadeh S; Javadian B; Sadeghian S
    Biopharm Drug Dispos; 2006 Oct; 27(7):329-34. PubMed ID: 16892180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A validated SIM GC/MS method for the simultaneous determination of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in biological matrices and its application to in vitro CYP2D6 and CYP3A4 inhibition study.
    Spanakis M; Vizirianakis IS; Mironidou-Tzouveleki M; Niopas I
    Biomed Chromatogr; 2009 Nov; 23(11):1131-7. PubMed ID: 19444798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo.
    Lowry JA; Kearns GL; Abdel-Rahman SM; Nafziger AN; Khan IS; Kashuba AD; Schuetz EG; Bertino JS; van den Anker JN; Leeder JS
    Clin Pharmacol Ther; 2003 Mar; 73(3):209-22. PubMed ID: 12621386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.
    Gorski JC; Huang SM; Pinto A; Hamman MA; Hilligoss JK; Zaheer NA; Desai M; Miller M; Hall SD
    Clin Pharmacol Ther; 2004 Jan; 75(1):89-100. PubMed ID: 14749695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism.
    Yasui N; Otani K; Kaneko S; Ohkubo T; Osanai T; Sugawara K; Chiba K; Ishizaki T
    Clin Pharmacol Ther; 1996 May; 59(5):514-9. PubMed ID: 8646822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Verapamil metabolite exposure in older and younger men during steady-state oral verapamil administration.
    Abernethy DR; Wainer IW; Anacleto AI
    Drug Metab Dispos; 2000 Jul; 28(7):760-5. PubMed ID: 10859149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers.
    Markowitz JS; Donovan JL; Devane CL; Taylor RM; Ruan Y; Wang JS; Chavin KD
    Clin Pharmacol Ther; 2003 Dec; 74(6):536-42. PubMed ID: 14663456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
    Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
    J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity.
    Kashuba AD; Nafziger AN; Kearns GL; Leeder JS; Gotschall R; Gaedigk A; Bertino JS
    Pharmacogenetics; 1999 Aug; 9(4):453-62. PubMed ID: 10780265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats.
    Choi JS; Burm JP
    Arch Pharm Res; 2008 Sep; 31(9):1200-4. PubMed ID: 18806964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.